Do plaintiffs’ experts get to put junk science before juries more often than their opinions are excluded? The answer is a resounding “probably.” Even in light of the December 2023 amendment to Federal Rule of Evidence and its...more
3/27/2025
/ Federal Rules of Evidence ,
Healthcare ,
Litigation Strategies ,
Manufacturers ,
Medical Research ,
Pharmaceutical Industry ,
Public Health ,
Regulatory Requirements ,
Risk Assessment ,
Risk Management ,
Vaccinations